Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia.

Pearson JM, Tan SF, Sharma A, Annageldiyev C, Fox TE, Abad JL, Fabrias G, Desai D, Amin S, Wang HG, Cabot MC, Claxton DF, Kester M, Feith DJ, Loughran TP.

Mol Cancer Res. 2020 Mar;18(3):352-363. doi: 10.1158/1541-7786.MCR-19-0619. Epub 2019 Nov 19.

PMID:
31744877
2.

Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML.

Zhao C, Jia B, Wang M, Schell TD, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Songdej N, Sivik JM, Hohl RJ, Zeng H, Zheng H.

Br J Haematol. 2020 Mar;188(5):674-684. doi: 10.1111/bjh.16228. Epub 2019 Oct 1.

3.

Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia.

Barth BM, Wang W, Toran PT, Fox TE, Annageldiyev C, Ondrasik RM, Keasey NR, Brown TJ, Devine VG, Sullivan EC, Cote AL, Papakotsi V, Tan SF, Shanmugavelandy SS, Deering TG, Needle DB, Stern ST, Zhu J, Liao J, Viny AD, Feith DJ, Levine RL, Wang HG, Loughran TP Jr, Sharma A, Kester M, Claxton DF.

Blood Adv. 2019 Sep 10;3(17):2598-2603. doi: 10.1182/bloodadvances.2018021295. No abstract available.

4.

Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells.

Kao LP, Morad SAF, Davis TS, MacDougall MR, Kassai M, Abdelmageed N, Fox TE, Kester M, Loughran TP Jr, Abad JL, Fabrias G, Tan SF, Feith DJ, Claxton DF, Spiegel S, Fisher-Wellman KH, Cabot MC.

J Lipid Res. 2019 Sep;60(9):1590-1602. doi: 10.1194/jlr.RA119000251. Epub 2019 Jul 30.

PMID:
31363040
5.

Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).

Kempin S, Sun Z, Kay NE, Paietta EM, Mazza JJ, Ketterling RP, Frankfurt O, Claxton DF, Saltzman JN, Srkalovic G, Callander NS, Gross G, Tallman MS.

Acta Haematol. 2019;142(4):224-232. doi: 10.1159/000500164. Epub 2019 Jul 23.

PMID:
31336367
6.

Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma.

Spurgeon SE, Sharma K, Claxton DF, Ehmann C, Pu J, Shimko S, Stewart A, Subbiah N, Palmbach G, LeBlanc F, Latour E, Chen Y, Mori M, Hasanali Z, Epner EM.

Br J Haematol. 2019 Sep;186(6):845-854. doi: 10.1111/bjh.16008. Epub 2019 Jun 9.

PMID:
31177537
7.

Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant-a pilot study.

Pu JJ, Poulose J, Malysz J, Zhu J, Fanburg-Smith JC, Claxton DF, Bayerl MG.

Br J Haematol. 2019 Sep;186(5):e130-e133. doi: 10.1111/bjh.15967. Epub 2019 May 22. No abstract available.

PMID:
31115038
8.

Downregulation of CD73 associates with T cell exhaustion in AML patients.

Kong Y, Jia B, Zhao C, Claxton DF, Sharma A, Annageldiyev C, Fotos JS, Zeng H, Paulson RF, Prabhu KS, Zheng H.

J Hematol Oncol. 2019 Apr 24;12(1):40. doi: 10.1186/s13045-019-0728-3.

9.

Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.

Tan SF, Dunton W, Liu X, Fox TE, Morad SAF, Desai D, Doi K, Conaway MR, Amin S, Claxton DF, Wang HG, Kester M, Cabot MC, Feith DJ, Loughran TP Jr.

J Lipid Res. 2019 Jun;60(6):1078-1086. doi: 10.1194/jlr.M091876. Epub 2019 Apr 8.

PMID:
30962310
10.

Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity.

Kokolus KM, Haley JS, Koubek EJ, Gowda R, Dinavahi SS, Sharma A, Claxton DF, Helm KF, Drabick JJ, Robertson GP, Neighbors JD, Hohl RJ, Schell TD.

Oncoimmunology. 2018 Nov 11;8(2):e1539614. doi: 10.1080/2162402X.2018.1539614. eCollection 2019.

11.

Eomes+T-betlow CD8+ T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia.

Jia B, Zhao C, Rakszawski KL, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Wang M, Shike H, Bayerl MG, Sivik JM, Schell TD, Drabick JJ, Hohl RJ, Zheng H.

Cancer Res. 2019 Apr 1;79(7):1635-1645. doi: 10.1158/0008-5472.CAN-18-3107. Epub 2019 Feb 1.

12.

Combinatorial Efficacy of Quercitin and Nanoliposomal Ceramide for Acute Myeloid Leukemia.

McGill CM, Brown TJ, Fisher LN, Gustafson SJ, Dunlap KL, Beck AJ, Toran PT, Claxton DF, Barth BM.

Int J Biopharm Sci. 2018;1(1). pii: 106. doi: 10.31021/ijbs.20181106. Epub 2018 Jan 31.

13.

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA.

Blood. 2019 Apr 4;133(14):1548-1559. doi: 10.1182/blood-2018-10-881961. Epub 2019 Jan 18. Erratum in: Blood. 2019 Sep 26;134(13):1111.

14.

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.

Wang L, Jia B, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Khawaja MR, Sivik J, Han J, Hohl RJ, Zheng H.

Oncoimmunology. 2018 Jul 11;7(9):e1469594. doi: 10.1080/2162402X.2018.1469594. eCollection 2018.

15.

Therapeutic effect of Northern Labrador tea extracts for acute myeloid leukemia.

McGill CM, Tomco PL, Ondrasik RM, Belknap KC, Dwyer GK, Quinlan DJ, Kircher TA, Andam CP, Brown TJ, Claxton DF, Barth BM.

Phytother Res. 2018 Aug;32(8):1636-1641. doi: 10.1002/ptr.6091. Epub 2018 Apr 27.

PMID:
29701283
16.

Therapeutic Effect of Blueberry Extracts for Acute Myeloid Leukemia.

McGill CM, Brown TJ, Cheng YY, Fisher LN, Shanmugavelandy SS, Gustafson SJ, Dunlap KL, Lila MA, Kester M, Toran PT, Claxton DF, Barth BM.

Int J Biopharm Sci. 2018 Jan;1(1). pii: 102. Epub 2018 Jan 2.

17.

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients.

Jia B, Wang L, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Rizvi S, Shike H, Bayerl M, Schell TD, Hohl RJ, Zheng H.

Blood Cancer J. 2018 Mar 21;8(3):34. doi: 10.1038/s41408-018-0069-4. No abstract available.

18.

Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia.

Van de Louw A, Desai RJ, Zhu J, Claxton DF.

Leuk Lymphoma. 2018 Oct;59(10):2369-2376. doi: 10.1080/10428194.2018.1435874. Epub 2018 Feb 12.

PMID:
29431568
19.

Orbital Epstein-Barr Virus-Positive Polymorphic B-Cell Lymphoproliferative Disorder in an Apparently Immunocompetent Woman.

Abendroth MD, Bayerl MG, Wilkinson MJ, Claxton DF, Specht CS.

Ocul Oncol Pathol. 2017 Dec;4(1):61-65. doi: 10.1159/000478747. Epub 2017 Aug 11.

20.

STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia.

Doshi UA, Shaw J, Fox TE, Claxton DF, Loughran TP, Kester M.

Signal Transduct Target Ther. 2017 Oct 27;2:17051. doi: 10.1038/sigtrans.2017.51. eCollection 2017.

21.

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.

Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Khan N, Oster W, Allen JE, El-Deiry WS.

Cell Cycle. 2018;17(4):468-478. doi: 10.1080/15384101.2017.1403689. Epub 2018 Feb 19.

22.

SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models.

Hengst JA, Dick TE, Sharma A, Doi K, Hegde S, Tan SF, Geffert LM, Fox TE, Sharma AK, Desai D, Amin S, Kester M, Loughran TP, Paulson RF, Claxton DF, Wang HG, Yun JK.

Cancer Transl Med. 2017 Jul-Aug;3(4):109-121. doi: 10.4103/ctm.ctm_7_17. Epub 2017 Aug 14.

23.

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.

Zhu L, Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Palmisiano ND, Wang M, Jia B, Bayerl M, Schell TD, Hohl RJ, Zeng H, Zheng H.

J Hematol Oncol. 2017 Jun 19;10(1):124. doi: 10.1186/s13045-017-0486-z.

24.

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C.

Ann Oncol. 2017 May 1;28(5):1050-1056. doi: 10.1093/annonc/mdx031.

25.

Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability.

Salzberg AC, Harris-Becker A, Popova EY, Keasey N, Loughran TP, Claxton DF, Grigoryev SA.

PLoS One. 2017 Mar 16;12(3):e0173723. doi: 10.1371/journal.pone.0173723. eCollection 2017.

26.

PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features.

Teye EK, Sido A, Xin P, Finnberg NK, Gokare P, Kawasawa YI, Salzberg AC, Shimko S, Bayerl M, Ehmann WC, Claxton DF, Rybka WB, Drabick JJ, Wang HG, Abraham T, El-Deiry WS, Brodsky RA, J Hohl R, Pu JJ.

Oncotarget. 2017 May 2;8(18):29887-29905. doi: 10.18632/oncotarget.15136.

27.

Therapeutic inhibition of BCL-2 and related family members.

Levy MA, Claxton DF.

Expert Opin Investig Drugs. 2017 Mar;26(3):293-301. doi: 10.1080/13543784.2017.1290078. Epub 2017 Feb 9. Review.

PMID:
28161988
28.

Chest radiographic and CT findings in hyperleukocytic acute myeloid leukemia: A retrospective cohort study of 73 patients.

Stefanski M, Jamis-Dow C, Bayerl M, Desai RJ, Claxton DF, Van de Louw A.

Medicine (Baltimore). 2016 Nov;95(44):e5285.

29.

Acid ceramidase is upregulated in AML and represents a novel therapeutic target.

Tan SF, Liu X, Fox TE, Barth BM, Sharma A, Turner SD, Awwad A, Dewey A, Doi K, Spitzer B, Shah MV, Morad SA, Desai D, Amin S, Zhu J, Liao J, Yun J, Kester M, Claxton DF, Wang HG, Cabot MC, Schuchman EH, Levine RL, Feith DJ, Loughran TP Jr.

Oncotarget. 2016 Dec 13;7(50):83208-83222. doi: 10.18632/oncotarget.13079.

30.

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM.

Blood. 2016 Nov 3;128(18):2199-2205. Epub 2016 Sep 6.

PMID:
27601462
31.

Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model.

Liu Q, Chen L, Atkinson JM, Claxton DF, Wang HG.

Cell Death Dis. 2016 Sep 8;7(9):e2361. doi: 10.1038/cddis.2016.264.

32.

Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia.

Morad SA, Ryan TE, Neufer PD, Zeczycki TN, Davis TS, MacDougall MR, Fox TE, Tan SF, Feith DJ, Loughran TP Jr, Kester M, Claxton DF, Barth BM, Deering TG, Cabot MC.

J Lipid Res. 2016 Jul;57(7):1231-42. doi: 10.1194/jlr.M067389. Epub 2016 May 2.

33.

T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients.

Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, Rybka WB, George MR, Zeng H, Zheng H.

Clin Cancer Res. 2016 Jun 15;22(12):3057-66. doi: 10.1158/1078-0432.CCR-15-2626. Epub 2016 Jan 13.

34.

Hypoxemia During Extreme Hyperleukocytosis: How Spurious?

Van de Louw A, Desai RJ, Schneider CW, Claxton DF.

Respir Care. 2016 Jan;61(1):8-14. doi: 10.4187/respcare.04196. Epub 2015 Sep 29.

35.

Initial respiratory status in hyperleukocytic acute myeloid leukemia: prognostic significance and effect of leukapheresis.

Van de Louw A, Schneider CW, Desai RJ, Claxton DF.

Leuk Lymphoma. 2016;57(6):1319-26. doi: 10.3109/10428194.2015.1094695. Epub 2015 Oct 13.

PMID:
26374497
36.

Intractable myoclonic seizures in an allogeneic stem cell transplant recipient: A rare case of myoclonic epilepsy.

Robuccio A, Ssentongo P, Sather MD, Claxton DF, Gilliam FG.

Epilepsy Behav Case Rep. 2015 Aug 8;4:48-51. doi: 10.1016/j.ebcr.2015.06.005. eCollection 2015.

37.

PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.

Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, Zeng H, Schell TD, Zheng H.

Blood Cancer J. 2015 Jul 31;5:e330. doi: 10.1038/bcj.2015.58.

38.

Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.

Morad SA, Tan SF, Feith DJ, Kester M, Claxton DF, Loughran TP Jr, Barth BM, Fox TE, Cabot MC.

Biochim Biophys Acta. 2015 Jul;1851(7):919-28. doi: 10.1016/j.bbalip.2015.03.001. Epub 2015 Mar 10.

39.

Extracts of Devil's club (Oplopanax horridus) exert therapeutic efficacy in experimental models of acute myeloid leukemia.

McGill CM, Alba-Rodriguez EJ, Li S, Benson CJ, Ondrasik RM, Fisher LN, Claxton DF, Barth BM.

Phytother Res. 2014 Sep;28(9):1308-14.

PMID:
25340187
40.

Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic Evaluation.

Barth BM, Keasey NR, Wang X, Shanmugavelandy SS, Rampal R, Hricik T, Cabot MC, Kester M, Wang HG, Shultz LD, Tallman MS, Levine RL, Loughran TP Jr, Claxton DF.

J Leuk (Los Angel). 2014 Sep;2(3). pii: 146. doi: 10.4172/2329-6917.1000146. Epub 2014 Jul 25.

41.

Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia.

Abbi KK, Rybka W, Ehmann WC, Claxton DF.

Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):41-6. doi: 10.1016/j.clml.2014.06.005. Epub 2014 Jun 11.

PMID:
25085441
42.

Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.

Bisen A, Claxton DF.

Adv Exp Med Biol. 2013;779:179-96. doi: 10.1007/978-1-4614-6176-0_8. Review.

PMID:
23288640
43.

Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer.

Tacelosky DM, Creecy AE, Shanmugavelandy SS, Smith JP, Claxton DF, Adair JH, Kester M, Barth BM.

Discov Med. 2012 Apr;13(71):275-85. Review.

44.

Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia.

Barth BM, I Altinoğlu E, Shanmugavelandy SS, Kaiser JM, Crespo-Gonzalez D, DiVittore NA, McGovern C, Goff TM, Keasey NR, Adair JH, Loughran TP Jr, Claxton DF, Kester M.

ACS Nano. 2011 Jul 26;5(7):5325-37. doi: 10.1021/nn2005766. Epub 2011 Jul 8.

PMID:
21675727
45.

Out foxing bcr-abl.

Claxton DF.

Cancer Biol Ther. 2011 Apr 15;11(8):769-70. Epub 2011 Apr 15. No abstract available.

PMID:
21358259
46.

A non-coding cationic lipid DNA complex produces lasting anti-leukemic effects.

Keasey N, Herse Z, Chang S, Liggitt DH, Lay M, Fairman J, Claxton DF.

Cancer Biol Ther. 2010 Sep 15;10(6):625-31. Epub 2010 Sep 13.

47.

SIRS criteria in prediction of septic shock in hospitalized patients with hematologic malignancies.

Ibrahim S, Claxton DF.

Cancer Biol Ther. 2009 Jun;8(12):1101. No abstract available.

PMID:
19652525
48.

Oral administration of analgesia and anxiolysis for pain associated with bone marrow biopsy.

Talamo G, Liao J, Bayerl MG, Claxton DF, Zangari M.

Support Care Cancer. 2010 Mar;18(3):301-5. doi: 10.1007/s00520-009-0652-0. Epub 2009 May 21.

PMID:
19455356
49.

BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma.

Talamo G, Claxton DF, Dougherty DW, Ehmann CW, Sivik J, Drabick JJ, Rybka W.

Bone Marrow Transplant. 2009 Aug;44(3):157-61. doi: 10.1038/bmt.2008.446. Epub 2009 Feb 9.

PMID:
19204716
50.

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD.

Blood. 2009 Jan 8;113(2):299-305. doi: 10.1182/blood-2008-02-137943. Epub 2008 Oct 17.

Supplemental Content

Loading ...
Support Center